Endoscopic Ultrasound Clinical Trial
Official title:
EUS-guided Therapy vs Non-selective Beta Blocker for the Primary Prophylaxis of Gastric Varices Bleed: a Randomized Controlled Trial
NCT number | NCT05859009 |
Other study ID # | 23-066 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | July 1, 2023 |
Est. completion date | July 1, 2026 |
Verified date | December 2023 |
Source | Unity Health Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary prophylaxis of gastric varices is an important area of research, as gastric varices are a common complication of cirrhosis of the liver. Cirrhosis is a condition in which the liver becomes scarred and loses its ability to function properly, and it is a leading cause of morbidity and mortality worldwide. Gastric varices occur in up to 30% of patients with cirrhosis, and they can rupture, leading to life-threatening bleeding. The clinical, epidemiological, and public health context of primary prophylaxis of gastric varices is therefore the need to prevent the development of this complication in patients at risk for cirrhosis and to reduce the associated morbidity and mortality. The clinical trials on primary prophylaxis of gastric varices are therefore focused on evaluating the safety and efficacy of various interventions, such as beta-blockers and endoscopic techniques, in reducing the risk of gastric varices in patients with cirrhosis. The goal of this trial is to find the most effective and safe strategies for primary prophylaxis of gastric varices, in order to improve the outcomes for patients with cirrhosis.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | July 1, 2026 |
Est. primary completion date | July 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients 18 years or older - Referred to St. Michael's Hospital (SMH) for esophagogastroduodenoscopy (EGD) screening for varices - Patients with GOV-2 or IGV-1 varices with the size = 10 mm Exclusion Criteria: - Age >75 and < 18 years - Pregnancy - Contraindications to beta-blockers and cyanoacrylate injection - Prior treatment for prevention of bleeding from patients on beta-blockers - Hepatic encephalopathy grade III/IV - Hepatorenal syndrome, hepatocellular carcinoma, presence of deep jaundice (serum bilirubin >170 mmol/L) - Cardiorespiratory failure - Co-existing large oesophageal varices which require endoscopic intervention - Child-Pugh C (score of 10-15 indicating decompensated disease) - Presence of serious complications of liver cirrhosis |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Unity Health Toronto |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety of the procedure | -Adverse Event (AE) rate for both methods | - Follow-up visit after 3 months | |
Other | Safety of the procedure | -AE rate for both methods | - Follow-up visit after 6 months | |
Other | Safety of the procedure | -AE rate for both methods | - Follow-up visit after 9 months | |
Primary | Assessment of NSBB (Propanolol), EUS-guided combined therapy (coils + glue) of GOV-2 and IGV-1 | - incidence of bleeding during the follow-up | 3 months | |
Primary | Assessment of NSBB (Propanolol), EUS-guided combined therapy (coils + glue) of GOV-2 and IGV-1 | -regression of gastric varices | 3 months | |
Primary | Assessment of NSBB (Propanolol), EUS-guided combined therapy (coils + glue) of GOV-2 and IGV-1 | - incidence of bleeding during the follow-up | 6 months | |
Primary | Assessment of NSBB (Propanolol), EUS-guided combined therapy (coils + glue) of GOV-2 and IGV-1 | -regression of gastric varices | 6 months | |
Primary | Assessment of NSBB (Propanolol), EUS-guided combined therapy (coils + glue) of GOV-2 and IGV-1 | - incidence of bleeding during the follow-up | 9 months | |
Primary | Assessment of NSBB (Propanolol), EUS-guided combined therapy (coils + glue) of GOV-2 and IGV-1 | -regression of gastric varices | 9 months | |
Secondary | Estimation if any of the study arms is better for regression in size of varix | Assessing Size of Varix (mm) | 3 months | |
Secondary | Estimation if any of the study arms is better for regression in size of varix | Assessing Size of Varix (mm) | 6 months | |
Secondary | Estimation if any of the study arms is better for regression in size of varix | Assessing Size of Varix (mm) | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05566093 -
EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors
|
N/A | |
Terminated |
NCT06371716 -
Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions
|
N/A | |
Not yet recruiting |
NCT05421520 -
Effectiveness of an Ai-based Endoscopic Ultrasound Navigation System in the Training of Endoscopic Ultrasonics
|
N/A | |
Recruiting |
NCT05131776 -
EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma.
|
Phase 2/Phase 3 | |
Recruiting |
NCT04820036 -
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
|
N/A | |
Completed |
NCT03738280 -
Non-hypovascular Solid Pancreatic Lesions: Role of EUS
|
||
Completed |
NCT04834193 -
Wet-suction Versus Slow-pull for EUS-FNB of Solid Lesions
|
N/A | |
Completed |
NCT06315439 -
Digital Confocal Microscopy for Real-time Diagnosis of Pancreatic Solid Lesion
|
||
Terminated |
NCT04306211 -
Comparison of Oxygenation Between Nasal PAP vs Nasal During Propofol-based Sedation for EUS
|
N/A |